October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
19 citations
,
April 2017 in “Synapse” Blocking allopregnanolone production in mice makes them more anxious after stress, but this can be reversed with a drug that mimics allopregnanolone.
Avicennia Marina extract and avicequinone C can reduce hair loss hormone production and increase hair growth factors, suggesting they could be used to treat androgenic alopecia.
21 citations
,
January 2010 in “JOURNAL OF HEALTH SCIENCE” Abietic acid from pine resin can effectively inhibit testosterone 5α-reductase.
52 citations
,
January 2005 in “PubMed” Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
1 citations
,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
2 citations
,
March 2022 in “Dermatologic Therapy” Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
October 2009 in “Reactions Weekly” A woman developed lupus after taking hydroxyurea for two years.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
50 citations
,
September 1975 in “American Heart Journal” Minoxidil effectively controls blood pressure in severe cases, but may cause fluid retention and edema.
Cadd4 effectively reduces cholesterol levels without side effects.
14 citations
,
October 1977 in “The Lancet” 1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
73 citations
,
September 2016 in “Journal of Translational Medicine” Some heart drugs show promise for other conditions, but more research is needed to confirm their effectiveness and safety.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
1 citations
,
September 2021 in “Dermatologic Therapy” AC5 improves hair loss and hair quality with high satisfaction rates.